Efficacy of Nemiralisib in Chronic Obstructive Pulmonary Disease: A Systematic Review
- 19 March 2024
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 46 (4) , 360-367
Abstract
No abstract availableKeywords
Funding Information
- Zhejiang Province Natural Science Foundation
- Chinese Medicine Research Program of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
This publication has 34 references indexed in Scilit:
- Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysisThe Lancet Respiratory Medicine, 2022
- Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPDPulmonary Pharmacology & Therapeutics, 2017
- The PI3K Pathway in Human DiseaseCell, 2017
- Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory DiseaseJournal of Medicinal Chemistry, 2015
- PI3K inhibitors in inflammation, autoimmunity and cancerCurrent Opinion in Pharmacology, 2015
- Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary diseaseJournal of Allergy and Clinical Immunology, 2014
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiencyNature Immunology, 2013
- New anti-inflammatory targets for chronic obstructive pulmonary diseaseNature Reviews Drug Discovery, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012